JP2021524446A5 - - Google Patents

Info

Publication number
JP2021524446A5
JP2021524446A5 JP2020564462A JP2020564462A JP2021524446A5 JP 2021524446 A5 JP2021524446 A5 JP 2021524446A5 JP 2020564462 A JP2020564462 A JP 2020564462A JP 2020564462 A JP2020564462 A JP 2020564462A JP 2021524446 A5 JP2021524446 A5 JP 2021524446A5
Authority
JP
Japan
Prior art keywords
tumor
composition according
immunotoxin
antigen
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020564462A
Other languages
English (en)
Japanese (ja)
Other versions
JP7536295B2 (ja
JP2021524446A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/032671 external-priority patent/WO2019222504A1/en
Publication of JP2021524446A publication Critical patent/JP2021524446A/ja
Publication of JP2021524446A5 publication Critical patent/JP2021524446A5/ja
Priority to JP2024124917A priority Critical patent/JP2024163118A/ja
Application granted granted Critical
Publication of JP7536295B2 publication Critical patent/JP7536295B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020564462A 2018-05-16 2019-05-16 免疫毒素とチェックポイント阻害剤との組み合わせを用いるネオアジュバントがん処置 Active JP7536295B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024124917A JP2024163118A (ja) 2018-05-16 2024-07-31 免疫毒素とチェックポイント阻害剤との組み合わせを用いるネオアジュバントがん処置

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862672150P 2018-05-16 2018-05-16
US62/672,150 2018-05-16
US201862675263P 2018-05-23 2018-05-23
US62/675,263 2018-05-23
US201962844857P 2019-05-08 2019-05-08
US62/844,857 2019-05-08
PCT/US2019/032671 WO2019222504A1 (en) 2018-05-16 2019-05-16 Neoadjuvant cancer treatment with immunotoxin and checkpoint inhibitor combination

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024124917A Division JP2024163118A (ja) 2018-05-16 2024-07-31 免疫毒素とチェックポイント阻害剤との組み合わせを用いるネオアジュバントがん処置

Publications (3)

Publication Number Publication Date
JP2021524446A JP2021524446A (ja) 2021-09-13
JP2021524446A5 true JP2021524446A5 (cg-RX-API-DMAC7.html) 2022-05-23
JP7536295B2 JP7536295B2 (ja) 2024-08-20

Family

ID=68540816

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020564462A Active JP7536295B2 (ja) 2018-05-16 2019-05-16 免疫毒素とチェックポイント阻害剤との組み合わせを用いるネオアジュバントがん処置
JP2024124917A Abandoned JP2024163118A (ja) 2018-05-16 2024-07-31 免疫毒素とチェックポイント阻害剤との組み合わせを用いるネオアジュバントがん処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024124917A Abandoned JP2024163118A (ja) 2018-05-16 2024-07-31 免疫毒素とチェックポイント阻害剤との組み合わせを用いるネオアジュバントがん処置

Country Status (5)

Country Link
US (1) US20210214442A1 (cg-RX-API-DMAC7.html)
EP (1) EP3793585A4 (cg-RX-API-DMAC7.html)
JP (2) JP7536295B2 (cg-RX-API-DMAC7.html)
CN (1) CN112423778A (cg-RX-API-DMAC7.html)
WO (1) WO2019222504A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12514927B2 (en) 2019-10-30 2026-01-06 Duke University Immunotherapy with combination therapy comprising an immunotoxin
CN117098539A (zh) * 2021-03-26 2023-11-21 阿斯利康(瑞典)有限公司 用于黑色素瘤的组合治疗

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US20090269343A1 (en) * 2008-04-11 2009-10-29 Duke University Dual Specific Immunotoxin for Brain Tumor Therapy
KR20170066546A (ko) * 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
US11065332B2 (en) * 2015-11-04 2021-07-20 Duke University Combination therapy of immunotoxin and checkpoint inhibitor
EP3411409B1 (en) * 2016-01-10 2025-10-08 Neotx Therapeutics Ltd. Anti pd-1/anti-pd-l1 antibodies for enhancing the potency of superantigen mediated cancer immunotherapy
WO2017214182A1 (en) * 2016-06-07 2017-12-14 The United States Of America. As Represented By The Secretary, Department Of Health & Human Services Fully human antibody targeting pdi for cancer immunotherapy
WO2018031507A1 (en) * 2016-08-09 2018-02-15 Angimmune, Llc Treatment of cancer using a combination of immunomodulation and check point inhibitors
CN109922819A (zh) * 2016-09-27 2019-06-21 西莱克塔生物科技公司 用于治疗癌症的重组免疫毒素
WO2018075357A1 (en) * 2016-10-17 2018-04-26 Duke University PRODUCTION OF IMMUNOTOXIN D2C7-(scdsFv)-PE38KDEL
WO2018156448A1 (en) * 2017-02-21 2018-08-30 The Board Of Regents Of The Uiversity Of Texas System Prediction and treatment of immunotherapeutic toxicity

Similar Documents

Publication Publication Date Title
JP2021511058A5 (cg-RX-API-DMAC7.html)
JP2021528423A5 (cg-RX-API-DMAC7.html)
JP2018508483A5 (cg-RX-API-DMAC7.html)
RU2018147413A (ru) PD-L1 специфические антитела
JP2017514461A5 (cg-RX-API-DMAC7.html)
JP2019515008A5 (cg-RX-API-DMAC7.html)
FI3932951T3 (fi) Menetelmiä ihosyövän hoitamiseksi antamalla PD-1-inhibiittoria
JP2018534933A5 (cg-RX-API-DMAC7.html)
JP2022512750A5 (cg-RX-API-DMAC7.html)
JP2009541492A5 (cg-RX-API-DMAC7.html)
JP2017507900A5 (cg-RX-API-DMAC7.html)
RU2013102225A (ru) АНТИТЕЛА ПРОТИВ Axl И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
JP2018505177A5 (cg-RX-API-DMAC7.html)
JP2016063817A5 (cg-RX-API-DMAC7.html)
JP2017501167A5 (cg-RX-API-DMAC7.html)
KR20200020902A (ko) 간세포암(hepatocellular carcinoma: HCC)에 대한 면역 치료
RU2018107693A (ru) Комбинированные виды лечения и их варианты применения и способы
RU2012131411A (ru) АНТИТЕЛА ПРОТИВ Bv8 И ИХ ПРИМЕНЕНИЕ
JP2024016024A5 (cg-RX-API-DMAC7.html)
JP2022512851A5 (cg-RX-API-DMAC7.html)
RU2014109093A (ru) Антитела против нейрегулина и их применение
JP2022553851A5 (cg-RX-API-DMAC7.html)
JP2023545084A5 (cg-RX-API-DMAC7.html)
JP2024533067A5 (cg-RX-API-DMAC7.html)
JP2021506817A5 (cg-RX-API-DMAC7.html)